Current practices in the management of chronic myeloid leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 1, 2013, Pages 48-54

  Kantarjian, Hagop M ^a   Larson, Richard A ^b   Cortés, Jorge E ^a   Deering, Kathleen L ^c   Mauro, Michael J ^d  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c EPI Q Inc   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

CML; Guidelines; Practice patterns; Survey; Tyrosine kinase inhibitors

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD CELL COUNT; BONE PAIN; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CROSS-SECTIONAL STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; FLUID RETENTION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HEALTH SURVEY; HEART FAILURE; HUMAN; LIVER DYSFUNCTION; MOLECULARLY TARGETED THERAPY; MUSCLE CRAMP; NEUTROPENIA; PERICARDIAL EFFUSION; PERICARDITIS; PERIORBITAL EDEMA; PHYSICIAN; PHYSICIAN ATTITUDE; PLEURA EFFUSION; PRACTICE GUIDELINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; UNITED STATES; WEIGHT GAIN;

ADULT; AGED; CROSS-SECTIONAL STUDIES; DATA COLLECTION; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; UNITED STATES;

EID: 84873315678     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2012.07.009     Document Type: Article

References (35)

1. H.M. Kantarjian, J. Cortes, F. Guilhot Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns Cancer 109 2007 1365 1375
2. G. Saglio, D.W. Kim, S. Issaragrisil Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia N Engl J Med 362 2010 2251 2259
3. H. Kantarjian, N.P. Shah, A. Hochhaus Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 362 2010 2260 2270
4. National Comprehensive Cancer Network NCCN: Clinical Practice Guidelines in Oncology, Chronic Myelogenous Leukemia Version 2 http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp 2012 Accessed February 1, 2012
5. M. Baccarani, J. Cortes, F. Pane Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet J Clin Oncol 27 2009 6041 6051
6. National Comprehensive Cancer Network NCCN: Clinical Practice Guidelines in Oncology, Chronic Myelogenous Leukemia Version 1 http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp 2010 Accessed January 31, 2010
7. B.J. Druker, F. Guilhot, S.G. O'Brien Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417
8. M. Deininger, S.G. O'Brien, F. Guilhot International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib Blood (ASH Annual Meeting Abstracts) 114 2009 462 [ASH Abstract 1126]
9. H. de Lavallade, J.F. Apperley, J.S. Khorashad Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis J Clin Oncol 26 2008 3358 3363
10. A. Quintás-Cardama, J.E. Cortes, S. O'Brien Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia Cancer 115 2009 2912 2921
11. S. Branford, T.P. Hughes, Z. Rudzki Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics Br J Haematol 107 1999 587 599
12. C. Schoch, S. Schnittger, S. Bursch Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases Leukemia 16 2002 53 59
13. E.J. Jabbour, A. Quintás-Cardama Molecular monitoring 101: helping your patients with CML understanding the meaning of molecular response Leuk Lymphoma 53 2012 1452 1460
14. T.P. Hughes, A. Hochhaus, S. Branford Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon and STI571 (IRIS) Blood 116 2010 3758 3765
15. J. Cortes, M. Talpaz, S. O'Brien Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate Clin Cancer Res 11 2005 3425 3432
16. I. Iacobucci, G. Saglio, G. Rosti Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients Clin Cancer Res 12 2006 3037 3042
17. F. Palandri, I. Iacobucci, S. Soverini Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response Clin Cancer Res 15 2009 1059 1063
18. P. Paschka, M.C. Müller, K. Merx Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha Low levels of residual disease are associated with continuous remission Leukemia 17 2003 1687 1694
19. D. Marin, D. Milojkovic, E. Olavarria European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor Blood 112 2008 4437 4444
20. R.D. Press, C. Galderisi, R. Yang A half-log increase in bcr-abl RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response Clin Cancer Res 13 2007 6136 6143
21. R.D. Press, Z. Love, A.A. Tronnes BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML Blood 107 2006 4250 4256
22. T.P. Hughes, J. Kaeda, S. Branford Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 2003 1423 1432
23. R. Hehlmann, M. Lauseker, S. Jung-Munkwitz Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia J Clin Oncol 29 2011 1634 1642
24. H. Kantarjian, S. O'Brien, J. Shan Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 112 2008 837 845
25. J. Cortes, A. Quintás-Cardama, H.M. Kantarjian Monitoring molecular response in chronic myeloid leukemia Cancer 117 2011 1113 1122
26. Y. Alvarado, H. Kantarjian, S. O'Brien Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase Cancer 115 2009 3709 3718
27. D. Marin, D. Milojkovic, E. Olavarria European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor Blood 112 2008 4437 4444
28. S. Branford, T. Hughes Detection of BCR-ABL mutations and resistance to imatinib mesylate Methods Mol Med 125 2006 93 106
29. A. Hochhaus, S. Kreil, A.S. Corbin Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy Leukemia 16 2002 2190 2196
30. E. Jabbour, H. Kantarjian, D. Jones Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate Leukemia 20 2006 1767 1773
31. T. Lahaye, B. Riehm, U. Berger Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up Cancer 103 2005 1659 1669
32. S. Soverini, S. Colarossi, A. Gnani Contribution of Abl kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia Clin Cancer Res 12 2006 7374 7379
33. S. Branford Chronic myeloid leukemia: molecular monitoring in clinical practice Hematology Am Soc Hematol Educ Program 2007 376 383
34. T. Hughes, M. Deininger, A. Hochhaus Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood 108 2006 28 37
35. National Comprehensive Cancer Network NCCN: Clinical Practice Guidelines in Oncology, Chronic Myelogenous Leukemia Version 2 http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp 2011 Accessed March 31, 2011